-
Regulatory May 10, 2024 EnglishINITIATOR PHARMA: Q1 2024 REPORT
-
Regulatory May 2, 2024 EnglishNotice to AGM in Initiator Pharma
-
Regulatory May 2, 2024 EnglishAnnual report and Remuneration report 2023 for Initiator Pharma A/S
-
Regulatory May 10, 2024 EnglishINITIATOR PHARMA: Q1 2024 REPORT
-
Regulatory May 2, 2024 EnglishAnnual report and Remuneration report 2023 for Initiator Pharma A/S
-
Regulatory February 23, 2024 EnglishINITIATOR PHARMA: YEAR END REPORT 2023
Share
Initiator Pharma Numbers
-
Expected Number of men affected by Erectile Dysfunction worldwide by 2025 322 million
-
Number of people worldwide that are diagnosed with Trigeminal Neuralgia every year: 15000
-
Men with Erectile Dysfunction who do not respond to drug therapy 40 %
Initiator Pharma currently has a portfolio of five projects, of which three are in clinical development and two are in preclinical development.
CEO letter
I am delighted to provide an update on Initiator Pharma’s progress and achievements during the start of 2024, building upon previous year’s successes where we achieved multiple important milestones across our development pipeline. We have continued to advance our goal of progressing novel drug candidates toward the market in a cost and time effective way, for the benefit of both patients in need of improved medical therapies and for our shareholders, while also strengthening our position in the market.